Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNK010
- Development stage
- Preclinical
- Lead developer
- Shanghai Enkai Cell Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
iNK010 is a chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy derived from induced pluripotent stem cells (iPSCs). Developed by Cell Inspire Biotechnology, it specifically targets G-protein coupled receptor family C group 5 member D (GPRC5D), a protein highly expressed on malignant plasma cells in multiple myeloma. To enhance therapeutic efficacy, the cells are engineered to secrete Interleukin-15 (IL-15), which promotes the persistence, proliferation, and antitumor activity of the NK cells within the tumor microenvironment. iNK010 is currently in preclinical development, with studies focused on in vivo PK/PD validation and investigator-initiated trials (IIT).
02
Targets
GPRC5DIL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on iNK010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNK010.